Literature DB >> 25448110

Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.

S Pecetta1, P Lo Surdo1, M Tontini1, D Proietti1, C Zambonelli1, M J Bottomley1, M Biagini1, F Berti1, P Costantino1, M R Romano2.   

Abstract

Glycoconjugate vaccines play an enormous role in preventing infectious diseases. The main carrier proteins used in commercial conjugate vaccines are the non-toxic mutant of diphtheria toxin (CRM197), diphtheria toxoid (DT) and tetanus toxoid (TT). Modern childhood routine vaccination schedules include the administration of several vaccines simultaneously or in close sequence, increasing the concern that the repeated exposure to conjugates based on these carrier proteins might interfere with the anti-polysaccharide response. Extending previous observations we show here that priming mice with CRM197 or DT does not suppress the response to the carbohydrate moiety of CRM197 meningococcal serogroup A (MenA) conjugates, while priming with DT can suppress the response to DT-MenA conjugates. To explain these findings we made use of biophysical and immunochemical techniques applied mainly to MenA conjugates. Differential scanning calorimetry and circular dichroism data revealed that the CRM197 structure was altered by the chemical conjugation, while DT and the formaldehyde-treated form of CRM197 were less impacted, depending on the degree of glycosylation. Investigating the binding and avidity properties of IgGs induced in mice by non-conjugated carriers, we found that CRM197 induced low levels of anti-carrier antibodies, with decreased avidity for its MenA conjugates and poor binding to DT and respective MenA conjugates. In contrast, DT induced high antibody titers able to bind with comparable avidity both the protein and its conjugates but showing very low avidity for CRM197 and related conjugates. The low intrinsic immunogenicity of CRM197 as compared to DT, the structural modifications induced by glycoconjugation and detoxification processes, resulting in conformational changes in CRM197 and DT epitopes with consequent alteration of the antibody recognition and avidity, might explain the different behavior of CRM197 and DT in a carrier priming context.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carrier induced epitopic suppression (CIES); Conjugate vaccines; Meningococcal conjugate vaccines; Meningococcal vaccines

Mesh:

Substances:

Year:  2014        PMID: 25448110     DOI: 10.1016/j.vaccine.2014.11.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model.

Authors:  Miaoge Xue; Linqi Yu; Lianzhi Jia; Yijian Li; Yuanjun Zeng; Tingdong Li; Shengxiang Ge; Ningshao Xia
Journal:  Hum Vaccin Immunother       Date:  2016-07-19       Impact factor: 3.452

2.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

3.  Synthesis and immunogenicity of the Mycobacterium tuberculosis arabinomannan-CRM197 conjugate.

Authors:  Yunsong Chang; Xin Meng; Yaxin Li; Jianmei Liang; Tingshen Li; Demei Meng; Tao Zhu; Peng Yu
Journal:  Medchemcomm       Date:  2019-04-02       Impact factor: 3.597

4.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

5.  On the use of adenovirus dodecahedron as a carrier for glycoconjugate vaccines.

Authors:  Maruthi Prasanna; Malgorzata Podsiadla-Bialoskorska; Damian Mielecki; Nicolas Ruffier; Amina Fateh; Annie Lambert; Mathieu Fanuel; Emilie Camberlein; Ewa Szolajska; Cyrille Grandjean
Journal:  Glycoconj J       Date:  2021-04-14       Impact factor: 2.916

6.  Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge.

Authors:  Addison E Stone; Sarah E Scheuermann; Colin N Haile; Gregory D Cuny; Marcela Lopez Velasquez; Joshua P Linhuber; Anantha L Duddupudi; Jennifer R Vigliaturo; Marco Pravetoni; Therese A Kosten; Thomas R Kosten; Elizabeth B Norton
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

7.  A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate.

Authors:  Ali Saber Abdelhameed; Gary G Adams; Gordon A Morris; Fahad M Almutairi; Pierre Duvivier; Karel Conrath; Stephen E Harding
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

8.  Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice.

Authors:  Essie Komla; Oscar B Torres; Rashmi Jalah; Agnieszka Sulima; Zoltan Beck; Carl R Alving; Arthur E Jacobson; Kenner C Rice; Gary R Matyas
Journal:  Vaccines (Basel)       Date:  2021-06-01

Review 9.  Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

Authors:  Michael Bröker; Francesco Berti; Paolo Costantino
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

10.  The Effect of Physicochemical Modification on the Function of Antibodies Induced by Anti-Nicotine Vaccine in Mice.

Authors:  Jennifer M Thorn; Keshab Bhattacharya; Renata Crutcher; Justin Sperry; Colleen Isele; Barbara Kelly; Libbey Yates; James Zobel; Ningli Zhang; Heather L Davis; Michael J McCluskie
Journal:  Vaccines (Basel)       Date:  2017-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.